Liquidia Corporation is a pharmaceutical company that designs, develops, and manufactures precision-engineered particle-based vaccines and therapeutics. Their advanced technology, known as PRINT®, allows for precise control over particle size, shape, and composition, leading to improved drug delivery and efficacy. With a focus on respiratory and pulmonary diseases, Liquidia is at the forefront of revolutionizing healthcare.
